High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.
about
Treatment for inclusion body myositisHow citation distortions create unfounded authority: analysis of a citation networkImmunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse modelIdiopathic Inflammatory Myopathies: Clinical Approach and ManagementThe Production Processes and Biological Effects of Intravenous ImmunoglobulinScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesImmunotherapies for Immune-Mediated Myopathies: A Current PerspectiveTherapeutic advances and future prospects in immune-mediated inflammatory myopathies.Treatment of sporadic inclusion body myositis with bimagrumabIntravenous immunoglobulin in neurological disease: a specialist review.Immunotherapy of inflammatory myopathies: practical approach and future prospects.Indications for IVIG in rheumatic diseasesUse of intravenous immunoglobulin for treatment of neurologic conditions: a systematic review.Efficacy of Intravenous Immunoglobulin in Neurological Diseases.Update on idiopathic inflammatory myopathies.Idiopathic inflammatory myopathies: current and future therapeutic options.Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.Intravenous immunoglobulin therapy in rheumatic diseases.Targeted immunotherapy trials for idiopathic inflammatory myopathies.Pathomechanisms of inflammatory myopathies: recent advances and implications for diagnosis and therapies.Update on treatment of inclusion body myositis.Diagnosis, pathogenesis and treatment of myositis: recent advances.Activity rating scales in adult muscle disease: what do they actually measure?Activity rating scales in adult muscle disease: how well do they actually measure?Inclusion body myositis: from immunopathology and degenerative mechanisms to treatment perspectives.Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.Amyloid deposits and inflammatory infiltrates in sporadic inclusion body myositis: the inflammatory egg comes before the degenerative chicken.Medication of inclusion body myositis: a systematic review.Subcutaneous Immunoglobulin Use in Inclusion Body Myositis: A Review of 6 Cases.Current pharmacological treatment of idiopathic inflammatory myopathies.Long-term observational study of sporadic inclusion body myositis.[Therapeutic administration of immunoglobulins].New advances in the treatment of neurological diseases using high dose intravenous immunoglobulins.Subcutaneous immunoglobulin treatment of inclusion-body myositis stabilizes dysphagia.Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution?Prognosis and prognostic factors in sporadic inclusion body myositis.Current Classification and Management of Inflammatory Myopathies.
P2860
Q24186948-61FC494A-BA9D-4D79-915A-75AFFA48AD92Q24260685-7AC7DC83-2347-42AB-AA91-C9CA15BF2631Q24608911-091E078A-C8C8-4250-BB44-6BBB1A9E9801Q26744705-FB83D3F7-4CCF-4196-91EA-5B8A8D9E5506Q26752540-681D72E7-5780-4C66-8231-B0BC0C5365E6Q26798209-E0895C74-21BC-486B-A767-D72573A4A637Q30699742-2BDC9586-DACE-4E3F-B944-A8F44BFB2DE7Q34409105-BCC7C740-028D-4D2E-AD50-7FC0F6FC1224Q34446951-E64A4FD2-0C15-4DA4-9632-C3A9DBF52E87Q34574581-63699729-1084-4E42-ADDA-7B3C1500694CQ34627294-7741EAB9-D129-4A96-B7BC-7AEB2F0A3E93Q35102141-BEAD7B2B-0CF2-41D9-87EF-13AF558AAA82Q36266356-5013643E-0D85-456E-832A-407E2F8F6143Q36484438-4A14AAED-7FC8-43A0-B411-96808A93BE84Q36504363-A67BF99D-E99E-47AA-B8DD-5B049045B15FQ37329526-6DD59186-B680-407A-B16C-1ACC48925D8BQ37866685-9E3B7808-6A2E-4B4F-9B92-33EDE5B7A030Q37873722-36168F67-A581-47F0-B22A-AA278A3F1E3AQ38023207-A97C66BA-E239-4953-8BC1-36A9376FBAABQ38089081-8DDBDC61-4DFD-46EB-ABD8-560FC6A483EEQ38093096-BC7A6F23-E78B-4AFD-A55A-69EBA6E47685Q38131849-5ACBE6F7-FDBB-4FB8-90AC-292CD3FCA00AQ38152335-6278926E-2295-44A6-842E-55B388892CDFQ38152377-647479E6-6B9A-40DC-9AA0-F7E90B83BC57Q38153797-2F9A329B-627A-4BD9-AE0F-1C19D623E086Q38308436-5BA3CABF-2050-4E6C-B29B-679FE8CEA021Q38314711-33AFC759-5B64-4E71-8902-E84916482C7BQ38540313-04C370F3-CCA9-4891-BDFD-B6A004205EC4Q38645740-7F8FB97E-5B72-4CCA-B731-8623AE5A2070Q38680762-EA1543FD-BD04-4E97-B5AF-C56877707760Q39698054-268075C5-08BF-42FC-A043-1EEFC3821B90Q40475039-D626D097-5C01-47B5-861E-DC917A8B48F1Q41173378-26DC132E-A4C7-4A72-9F0C-F398F82FD6E2Q43633205-C1A68669-5937-4554-B236-4A2C1D039C6AQ43916613-FF93FEAB-F1A8-44B2-AE08-195328747793Q53816522-963062CD-3AE1-4784-AC8D-229F84F8428CQ54560644-5B216AEB-52AF-47BB-8FA0-37007DE17C50Q54977148-C69E7C5F-48EE-4EA3-9777-1AD6226F6A41
P2860
High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@ast
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@en
type
label
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@ast
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@en
prefLabel
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@ast
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@en
P2093
P356
P1433
P1476
High-dose immunoglobulin thera ...... ind, placebo-controlled study.
@en
P2093
Lochmüller H
Müller-Felber W
Pongratz D
Schlotter B
Schröder M
P2888
P356
10.1007/S004150050005
P577
2000-01-01T00:00:00Z
P5875
P6179
1046824798